The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience

IF 1.2

EJHaem Pub Date : 2025-10-04 DOI:10.1002/jha2.70141

Dipal Mehta, Maria Gabriel, Nathan Adu-Poku, Nikolaos Kanellias, Xenofon Papanikolaou, Jonathan Sive, Neil Rabin, Rakesh Popat, Eileen M. Boyle, Lydia Lee, Kwee Yong, Agapi Parcharidou, Suganya Sivabalasingham, Karimali Keshwani, Ke Xu, Charalampia Kyriakou

{"title":"The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience","authors":"Dipal Mehta, Maria Gabriel, Nathan Adu-Poku, Nikolaos Kanellias, Xenofon Papanikolaou, Jonathan Sive, Neil Rabin, Rakesh Popat, Eileen M. Boyle, Lydia Lee, Kwee Yong, Agapi Parcharidou, Suganya Sivabalasingham, Karimali Keshwani, Ke Xu, Charalampia Kyriakou","doi":"10.1002/jha2.70141","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Radiotherapy (RT) is a well-established treatment modality in multiple myeloma (MM), particularly for skeletal-related events. However, its role is likely evolving with the introduction of modern systemic treatments.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a retrospective analysis of a large, single-centre MM cohort treated with contemporary protocols to describe current patterns of RT use.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>RT continues to offer clinical benefit, with shifting patterns of use observed compared to historical cohorts.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>RT remains relevant in the modern MM landscape and may hold increasing value in later treatment stages. We postulate a future role as bridging therapy prior to CAR-T/bispecific antibody treatment.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70141","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Radiotherapy (RT) is a well-established treatment modality in multiple myeloma (MM), particularly for skeletal-related events. However, its role is likely evolving with the introduction of modern systemic treatments.

Methods

We conducted a retrospective analysis of a large, single-centre MM cohort treated with contemporary protocols to describe current patterns of RT use.

Results

RT continues to offer clinical benefit, with shifting patterns of use observed compared to historical cohorts.

Conclusion

RT remains relevant in the modern MM landscape and may hold increasing value in later treatment stages. We postulate a future role as bridging therapy prior to CAR-T/bispecific antibody treatment.

Trial Registration

The authors have confirmed clinical trial registration is not needed for this submission

Abstract Image

查看原文本刊更多论文

放射治疗在现代多发性骨髓瘤患者中的作用：一个真实世界的单中心体验

放疗（RT）是多发性骨髓瘤（MM）的一种成熟的治疗方式，特别是对骨骼相关事件。然而，随着现代系统治疗的引入，它的作用可能会发生变化。方法：我们对采用当代治疗方案的大型单中心MM队列进行回顾性分析，以描述当前RT使用模式。结果放疗继续提供临床益处，与历史队列相比，观察到使用模式的变化。结论放射治疗在现代多发性骨髓瘤的治疗中仍然具有重要意义，并且在治疗后期可能具有越来越重要的价值。我们假设未来的作用是在CAR-T/双特异性抗体治疗之前作为桥接疗法。试验注册作者已确认该提交不需要临床试验注册

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量